Adial Pharmaceuticals (ADIL) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Adial Pharmaceuticals (ADIL) over the past year, losing 49.5% versus a loss of 60.3%. Over five years, TOVX leads with a -99.8% price change compared with -99.8% for ADIL. Adial Pharmaceuticals is the larger company by market cap ($10.4 million vs $10.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADIL | TOVX |
|---|---|---|
| Share price | $3.97 | $0.2212 |
| Market cap | $10.42M | $10.15M |
| 1-day change | 0.00% | -2.60% |
| YTD return | -27.82% | +8.14% |
| 1-year return | -60.30% | -49.53% |
| 5-year return | -99.84% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-20.65 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.50 | $0.86 |
| 52-week low | $1.31 | $0.16 |
| Distance from 52-week high | -62.19% | -74.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.82% | +1030.20% |
| Average volume | 56.16K | 525.96K |
| Shares outstanding | 2.63M | 45.89M |
| Employees | 5 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed ADIL by 10.8 percentage points over the past year.
About Adial Pharmaceuticals
ADIL stock →Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ADIL vs TOVX FAQ
Which is bigger, Adial Pharmaceuticals or Theriva Biologics?
Adial Pharmaceuticals (ADIL) is larger, with a market capitalization of $10.42M compared with $10.15M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, ADIL or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -60.30% for ADIL (price return, excluding dividends). Past performance does not predict future results.
Are Adial Pharmaceuticals and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.